• AI, Neuroscience, and Pharma's $500 Billion Problem: A Candid Talk with BMS’s Chief Medical Officer on the Future of Drug Development to Agentic Medical Science Liaisons
    Jun 29 2026

    In this episode of The Will Soliman Podcast, William Soliman sits down with Dr. Cristian Massacesi, high-energy Chief Medical Officer & Head of Drug Development at Bristol Myers Squibb (BMS). They explore how AI is reshaping drug discovery and clinical development, from target validation to trial execution.

    Topics include:

    • How AI is already accelerating drug discovery and clinical trials

    • Why neuroscience and neurodegenerative diseases have been so challenging—and why there’s new hope

    • The coming $500B patent cliff and what it means for Big Pharma and investors

    • The future of synthetic control arms, digital twins, and real-world evidence

    • How AI can augment medical affairs and MSLs, not replace them

    • Big changes in healthcare innovation

    Perfect for listeners in pharma, biotech, healthcare investing, clinical research & development, and medical affairs who want an inside view of where drug development is headed next.


    To Find Will Soliman on LinkedIn

    Related Sites:

    • Accreditation Council for Medical Affairs
    • Medical Science Liaisons
    • Prior Authorization and Field Reimbursement
    • White Manna Capital Partners

    Have a Topic or Guest Suggestion: Contact Us


    Show More Show Less
    41 mins
  • Drug Prices, Is Everything You’ve Been Told Wrong? What if the real reason medicines cost so much isn’t what you’ve been told?
    Jun 17 2026

    In this episode, Dr. William Soliman sits down with Dr. Michael Ybarra, Chief Medical Officer of PhRMA, the pharmaceutical industry's largest trade organization, for a candid conversation on drug pricing, healthcare policy, pharmaceutical innovation, patient access, and the future of medicine.

    Dr. Ybarra challenges some of the most common assumptions about prescription drug costs, explaining the role of PBMs, insurers, hospital markups, the 340B program, Medicare drug price negotiations, and the Inflation Reduction Act (IRA). The discussion also explores vaccine innovation, rare disease research, cancer breakthroughs, GLP-1 therapies, and the policies shaping the next generation of medical innovation.

    Whether you’re a healthcare professional, policymaker, patient advocate, investor, or simply trying to understand why healthcare costs continue to rise, this episode offers an inside look at one of the most important debates in healthcare today.

    Listen now to hear one of the leading physician voices from one of the largest trade organizations explain the forces shaping the future of medicine.

    To learn more about The Will Soliman Podcast

    Show More Show Less
    31 mins
  • You’re One of the Top NFL Prospect in America. Then Doctors Tell You That You Have Only Months to Live.
    Jun 5 2026

    At just 22 years old, Rob Long was living the dream, preparing himself to be one of the nation’s top football prospects out of Syracuse University, when everything changed in an instant.

    After being diagnosed with a rare, incurable brain cancer and undergoing surgery that removed 25% of his brain, Rob was forced into a fight far bigger than football. What followed is a story of survival, resilience, identity, and purpose.

    Today, his mission has shifted toward advancing rare disease research through UpLifting Athletes and helping others facing battles most people never see coming.

    Show More Show Less
    49 mins
  • Alex Zhavoronkov: Obesity, Longevity, AI-Designed Drugs, Billion Dollar Pharma Deals & the End of “Dinosaur AI"
    Jun 4 2026

    What happens when artificial intelligence starts designing medicines faster than the pharmaceutical industry can comprehend?

    In this explosive conversation, Dr. Will Soliman sits down with Alex Zhavoronkov, CEO, one of the most provocative voices in AI drug discovery and the founder of Insilico Medicine, to discuss the future of medicine, longevity, biotech, and the AI arms race transforming pharma.

    Fresh off Insilico’s multibillion-dollar deal with Eli Lilly, Alex explains why traditional pharmaceutical models are being disrupted, how AI-designed drugs are moving from theory to reality, and why most companies are still operating with what he calls “dinosaur AI.”

    Hear why Alex says China is beating everyone in drug discovery and new patents, and its impact.

    Show More Show Less
    59 mins
  • Do Vaccines Cause Autism, The Vaccine x Autism Myth, The Return of Measles and Other Preventable Diseases
    Jun 4 2026

    Are we losing the battle against preventable diseases? Watch Dr. Kelly Moore, CEO, and Dr. LJ Tan, Chief Policy Officer from Immunize.org, weigh in on “what is fact and myth”, along with Vaccine Committee Influencers, and what’s at risk for parents and children with Dr. Will Soliman.

    • The Vaccine - Autism Myth to address the persistent misinformation regarding vaccines and autism. Hear from the experts.
    • Understanding mRNA Technology as they break down how mRNA vaccines actually work and the recipe for your immune system.
    • The Return of Measles, with outbreaks rising, is the U.S. at risk of losing its measles elimination status, and what parents need to know.
    • Policy vs. Science: Exploring the role of the ACIP and Why Some States Are Now Opting to follow different clinical schedules.

    Tune in to learn how parents can protect their children and themselves.

    Show More Show Less
    49 mins
  • Patient Deaths, The Hidden Truths, And a Whistleblower's Battle with Big Pharma for Justice..
    Jun 4 2026

    For the first time, former pharmaceutical sales rep Allison Marie Zayas tells her story as a whistleblower. What she witnessed in the pharma industry was shocking: the patients caught in the middle and the fallout that followed. Hear how a top-performing sales rep risked it all to protect patients from the potential risk of death.

    Show More Show Less
    42 mins